✉news HealthMedicine first seen 2 d ago, last 1 d ago, peak #37
Orforglipron's Cardiovascular Data Raises the Bar for Oral GLP-1 Drugs
Original: Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It
Eli Lilly's experimental oral GLP-1 pill orforglipron reportedly delivered cardiovascular safety data (MACE outcomes) strong enough to reset expectations for the entire oral GLP-1 field. Commentators argue rival developers of oral weight-loss and diabetes drugs will now struggle to match this evidentiary standard in their own outcome trials.
Why now: New cardiovascular outcome data for a leading oral GLP-1 candidate has implications for competing drug programs and investor expectations.
Eli LillyOrforglipronoral GLP-1 drugs
Evidence
- Orforglipron’s MACE Data Just Raised the Evidentiary Bar for Every Oral GLP-1 Program Behind It · The Clinical Trial Vanguard
API: https://socialmediatrends-api.osmike.com/v1/trends/2867061